As Vice President, Nonclinical Development, Susan Sloan is responsible for IND-enabling and early-phase development activities that span preclinical, bioanalytical, and clinical pharmacology to transition programs from research to the clinic, and support programs in early-phase clinical development. Susan also oversees the Quality function. Susan joined Visterra in 2013 and has 20 years of biologics drug development experience. While at Visterra, Susan has overseen the transition of 4 research programs into early phase clinical development.
Prior to joining Visterra, Susan worked at MassBiologics, where she held various roles in research, development and quality. While at MassBiologics, she discovered a human monoclonal antibody directed against the rabies virus Glycoprotein. Her work led to the development of Rabishield, a rabies monoclonal antibody developed in partnership with Serum Institute of India that has been approved for human use in India.
Susan obtained her BS in biology from Pennsylvania State University and her PhD in Genetics from Tufts University Graduate School of Biomedical Sciences where she developed mouse models to explore the development of endocrine cells in the GI tract.
